Skip to content

Establishment of a strategy system for the treatment of prostate cancer with Chinese medicine and its superiority research program

Establishment of a strategy system for the treatment of prostate cancer with Chinese medicine and its superiority research program

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR1900002649
Enrollment
Unknown
Registered
2019-10-08
Start date
2019-09-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) Comply with the diagnostic criteria for prostate adenocarcinoma and give endocrine therapy; (2) Serum testosterone <50 ng / dl (1.7 nmol / L); (3) The physical strength of the study subjects is normal, and the karnofsky score exceeds 60 points, and is expected to survive for more than half a year; (4) Patient compliance is good and follow-up studies are possible; (5) Understand and sign the informed consent form. The above five conditions must be met at the same time.

Exclusion criteria

Exclusion criteria: (1) Patients with serious complications of prostate cancer; (2) Allergic to endocrine therapy drugs; (3) At the same time, it has obvious heart, brain and liver diseases; (4) Patients with primary malignant tumors of organs other than prostate cancer; (5) It is the end stage of the tumor, multiple organ failure.

Design outcomes

Primary

MeasureTime frame
PSA;therapeutic effect;

Secondary

MeasureTime frame
blood biochemical indexes;Tumor markers;

Countries

China

Contacts

Public ContactBai Zunguang

Guangdong Provincial Hospital of Chinese Medicine

zunguangbai@163.com+86 020-39318781

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026